Liraglutide
CGH-LiNASH
Novo Nordisk · Phase 3 · Status n/r · Enrollment 36
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Liraglutide | n/r | n/r | n/r | n/r |
| Bariatric Surgery | n/r | n/r | n/r | n/r |
| Diet modification and exercise | n/r | n/r | n/r | n/r |
Not shown
- Liraglutide: endpoint not reported
- Bariatric Surgery: endpoint not reported
- Diet modification and exercise: endpoint not reported